Clinical Trials
19 trialsNCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT05398640 2026-04-20
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
Iovance Biotherapeutics, Inc.
Available
NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT06063746 2026-01-08
Compassionate Use of Vidutolimod
Regeneron Pharmaceuticals
No longer available
NCT04489433 2025-12-18
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
Novartis
No longer available
NCT06590480 2025-12-18
RPL-EAP-001
Replimune, Inc.
No longer available
NCT03593499 2025-05-31
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
Biogen
No longer available
NCT04544202 2024-11-12
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
Novartis
No longer available
NCT04853602 2024-08-12
IFx-Hu2.0 Expanded Access Program
TuHURA Biosciences, Inc.
Available
NCT04289155 2022-03-17
Individual Patient Compassionate Use of GX-I7
Genexine, Inc.
No longer available
NCT04960891 2022-01-21
Non Applicable
Immunocore Ltd
Available
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available
NCT02297529 2019-10-31
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
Amgen
No longer available
NCT02083484 2018-01-26
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
Merck Sharp & Dohme LLC
No longer available
NCT02416232 2017-08-15
Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
GlaxoSmithKline
No longer available
NCT02186249 2017-02-08
CheckMate218
Bristol-Myers Squibb
No longer available
NCT02147951 2016-03-01
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
Amgen
No longer available
NCT01728051 2013-10-23
Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
Delcath Systems Inc.
No longer available
NCT00495066 2013-06-03
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
Bristol-Myers Squibb
No longer available